Abstract
Person-to-person transmission of SARS-CoV-2 virus has triggered a global emergency because of its potential to cause life-threatening Covid-19 disease. By comparison to paucisymptomatic virus clearance by most individuals, Covid-19 has been proposed to reflect insufficient and/or pathologically exaggerated immune responses. Here we identify a consensus peripheral blood immune signature across 63 hospital-treated Covid-19 patients who were otherwise highly heterogeneous. The core signature conspicuously blended adaptive B cell responses typical of virus infection or vaccination with discrete traits hitherto associated with sepsis, including monocyte and dendritic cell dampening, and hyperactivation and depletion of discrete T cell subsets. This blending of immuno-protective and immuno-pathogenic potentials was exemplified by near-universal CXCL10/IP10 upregulation, as occurred in SARS1 and MERS. Moreover, specific parameters including CXCL10/IP10 over-expression, T cell proliferation, and basophil and plasmacytoid dendritic cell depletion correlated, often prognostically, with Covid-19 progression, collectively composing a resource to inform SARS-CoV-2 pathobiology and risk-based patient stratification.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.immunophenotype.org/
Funding Statement
The work was supported by: a Cancer ImmunoTherapy Accelerator award from CRUK (AH; IDMDB), a CRUK City of London Major Cancer Centre studentship (M.J.); the Wellcome Trust (AH; PV; IZ; VS; 106292/Z/14/Z); the Rosetrees Trust (AH), King's Together Seed Fund (AH), Gamma Delta Therapeutics (RD, DD, SH), The John Black Charitable Foundation (AH), and the Francis Crick Institute, (AH, LM; FC) which receives core funding from Cancer Research UK (FC001093), the MRC (FC001093) and the Wellcome Trust (FC001093) (AH); NIHR Clinician Scientist Award CS-2016-16-011 (MSH); the NIHR BRC for the Infectious Diseases Biobank (JC, CM), and for support of Infection and Immunity (JE; RJ112/N027); EMBO ALTF 198-2018 (MMR); an Irvington Fellowship-Cancer Research Institute (DM); National Institute of Academic Anaesthesia BJA-RCOA PhD Fellowship WKR0-2018-0047 (MF), NIHR Fellowship (AD, YW); Clinical Immunology Research Fund for the King's College Hospital Charitable Trust (MI); UK MRC (MR/N013700/2) (CG); EMBL core funding and the European Union's Horizon 2020 Research and Innovation Programme under grant agreement #730879 (FG, JB, JM), and Estonian Research Council grant PRG377 (PP). The authors also acknowledge King's College London, the Francis Crick Institute and the EBI for institutional support. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol for patient recruitment and sampling, out of the intensive care setting, was approved by the committee of the Infectious Diseases Biobank of King's College London with reference number COV-250320. The protocol for healthy volunteer recruitment and sampling was similarly approved by the same committee as an amendment to an existing approval for healthy volunteer recruitment with reference number MJ1-031218b. Both approvals are granted under the terms of the Infectious Disease Biobank's ethics permission (reference 19/SC/0232) granted by the South Central Hampshire B Research Ethics Committee in 2019. Patient recruitment from the intensive care unit was undertaken through the ethics for the IMMERSE study approved by the South Central Berkshire Ethics Committee with reference number 19/SC/0187. Patient and control samples and data were anonymized at the point of sample collection by research nursing staff or clinicians involved in the COVID-IP project. We have complied with all relevant ethical regulations.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data and detailed protocols are available on the Covid-IP website (www.immunophenotype.org)
